| Opportunity Number | RFA-NS-26-001 |
|---|---|
| Agency | HHS-NIH11 |
| Application Deadline | 11/10/2026 |
| Award Amount | $50,135,013 |
| Status | Posted |
| Sector | Health |
| Cost Sharing | Not Required |
Fiscal Parameters & Taxonomy
Who Can Apply
Eligibility Intelligence
Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Eligible applicants must be clinical trial sites that participate in a phase 2/3 or phase 3 efficacy clinical trial (designed to provide pivotal data to support a marketing application) supported by a small business concern that is the FDA-designated sponsor of a drug or biological product which is the subject of an IND under section 505(i) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(i)) to prevent, diagnose, mitigate, treat, or cure ALS. The definition of a small business concern can be found in section 3(a) of the Small Business Act (15 U.S.C. 632(a)).Foreign Organizations/International CollaborationsNon-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
Program Description
CFDA Programs
Agency Contact
Related Intelligence Guides
In-depth editorial guides covering this agency's programs, eligibility requirements, and application strategies.